On September 24, 2025, Immuneering Corp announced a $25 million securities purchase agreement with Aventis Inc., contingent upon a future public offering that must generate at least $75 million. Additionally, interim data from a clinical trial showed 86% overall survival and 53% progression-free survival among 34 patients treated with atebimetinib, indicating promising results for pancreatic cancer treatment.